Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Operating Leases (2019 - 2025)

Eton Pharmaceuticals (ETON) has disclosed Operating Leases for 7 consecutive years, with $460000.0 as the latest value for Q4 2025.

  • Quarterly Operating Leases rose 329.91% to $460000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $460000.0 through Dec 2025, up 329.91% year-over-year, with the annual reading at $460000.0 for FY2025, 329.91% up from the prior year.
  • Operating Leases hit $460000.0 in Q4 2025 for Eton Pharmaceuticals, down from $480000.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $492000.0 in Q2 2025 to a low of $15000.0 in Q4 2021.
  • Historically, Operating Leases has averaged $135947.4 across 5 years, with a median of $79000.0 in 2021.
  • Biggest five-year swings in Operating Leases: crashed 84.85% in 2021 and later soared 613.33% in 2022.
  • Year by year, Operating Leases stood at $15000.0 in 2021, then skyrocketed by 613.33% to $107000.0 in 2022, then crashed by 79.44% to $22000.0 in 2023, then surged by 386.36% to $107000.0 in 2024, then skyrocketed by 329.91% to $460000.0 in 2025.
  • Business Quant data shows Operating Leases for ETON at $460000.0 in Q4 2025, $480000.0 in Q3 2025, and $492000.0 in Q2 2025.